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A B S T R A C T

Background: The COVID-19 pandemic has placed an enormous and growing burden on the population and health infrastructure, warranting innovative ways to mitigate risk of contracting and developing severe forms of this disease.
A growing body of literature raises the issue of vitamin C and vitamin D as a risk-assessment tool, and therapeutic option, in COVID-19.
Objective: The objective of this pilot study was to measure serum vitamin C and vitamin D levels in a cohort of patients
with critical COVID-19 illness in our community hospital ICU, correlate with other illness risk factors (age, BMI,
HgbA1c, smoking status), generate hypotheses, and suggest further therapeutic intervention studies.
Method: This pilot study included all 21 critically ill COVID-19 patients hospitalized in May 2020 in the ICU of North
Suburban Medical Center, Thornton, Colorado, in whose care the principal investigator (C.A.) was involved. We measured patients’ serum vitamin C and vitamin D levels, and standard risk factors like age, BMI, HbA1c, and smoking status. Variables in this study were gauged using descriptive statistics.
Results: Of 21 critically ill COVID-19 patients (15 males and 6 females, 17 Hispanic and 4 Caucasian, of median age 61
years, range 20–94), there were 11 survivors.
Serum levels of vitamin C and vitamin D were low in most of our critically ill COVID-19 ICU patients.
Older age and low vitamin C level appeared co-dependent risk factors for mortality from COVID-19 in our sample.
Insulin resistance and obesity were prevalent in our small cohort, but smoking was not.
Conclusion: Our pilot study found low serum levels of vitamin C and vitamin D in most of our critically ill COVID-19 ICU
patients. Older age and low vitamin C level appeared co-dependent risk factors for mortality. Many were also insulinresistant or diabetic, overweight or obese, known as independent risk factors for low vitamin C and vitamin D levels,
and for COVID-19.
These ﬁndings suggest the need to further explore whether caring for COVID-19 patients ought to routinely include
measuring and correcting serum vitamin C and vitamin D levels, and whether treating critically ill COVID-19 warrants
acute parenteral vitamin C and vitamin D replacement.

1. Introduction
The SARS-CoV-2 coronavirus disease was reported in 2019 (COVID-19),
reached pandemic extent in 2020, and has placed an enormous and growing
burden on the population at large, and on the health infrastructure. The

☆ Acknowledgements:Special thanks to Dr. George Bobustuc of Aurora Neuroscience Institute,
Milwaukee, WI, for valuable conceptual advice and manuscript review, and to our Patients and
their loved ones for entrusting us with their care.
⁎ Corresponding author.
E-mail addresses: carvinte@msn.com, (C. Arvinte), maharaj.singh@marquette.edu,
(M. Singh), marikpe@evms.edu. (P.E. Marik).

challenge posed by the multisystemic morbidity of COVID-19, and its high infectivity, calls for research on innovative ways to detect and mitigate the risk
factors leading to contracting and developing severe forms of COVID-19.
Whereas the role of nutrition in health and illness had been intuited
since ancient times; description of rickets dates back to the 17th century; ofﬁcial nutritional mandates to prevent scurvy were ﬁrst issued in the 18th
century and were conceptualized in medical science over 100 years ago
[1]; the discoveries of vitamin C and vitamin D and their physiologic
roles in the 1920s were landmarks in recognizing nutrition’s formal legitimacy in modern conventional medicine.
Despite established guidelines on Reference Daily Intake (RDI) for both
vitamin C and vitamin D and availability of fortiﬁed foods, chronic deﬁcits
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Age appeared to be a predictor of mortality from COVID-19. Every 10years’ increase in age increased risk of death 2.7-fold (OR = 2.7, 95% CI
= 1.01–5.10 p = 0.0474).
Older age and low vitamin C level appeared co-dependent risk factors
for mortality from COVID-19 in our sample, as suggested by Figs. 2 and 3.
We used age and serum vitamin C level as predictors of mortality in
three separate regression models.
-Firstly, age was used as a predictor of mortality in univariate regression
model, and the results showed that increasing age signiﬁcantly predicted
mortality.
-Secondly, we used serum vitamin level C as predictor of mortality in
univariate regression model, and results showed that serum vitamin C
was not a signiﬁcant predictor of mortality (Fig. 2).
-In the third multivariate regression model, we included both age and
serum level vitamin C in the model, and the results showed that both age
and serum level were non-signiﬁcant predictors of mortality (Fig. 3).
Overall correlation coefﬁcient between age and vitamin C level was
-0.2531 (p = 0.2816)
Survivors’ correlation coefﬁcient between age and vitamin C level was
-0.1954 (p = 0.5885)
Non-survivors’ correlation coefﬁcient between age and vitamin C level
was 0.1676 (p = 0.6435)
None of the above correlation coefﬁcients were statistically signiﬁcant.
Age was an independent predictor of mortality only when serum vitamin C level was not included in the regression model. When serum vitamin
C level was added as a predictor, along with age, both variables became
non-signiﬁcant predictors of mortality. This suggests an indirect evidence
that some of the signiﬁcant contribution of age to mortality came from
the serum vitamin C level (Fig. 3). Thus, age became non-signiﬁcant after
introduction of serum level in the regression model.
In other words, age without ﬁltering out the effect (unadjusted) of
serum vitamin C level (both age and vitamin C were contributing to mortality) was a signiﬁcant predictor of mortality. However, when effect of serum
vitamin C was taken out (adjusted), age became non-signiﬁcant predictor
mortality. This suggests that, in fact, serum vitamin C level contributed to
the signiﬁcance of age being predictor of mortality.
Insulin resistance and obesity were prevalent in our small cohort, with a
mean HbA1c of 7.6, and a mean BMI of 32.
Active smoking was surprisingly and encouragingly rare in our cohort,
with only 1 out of 21 patients smoking at the time of admission.

were documented in the general population [2,3], and in the in-hospital patients [4]. The biological culprit behind the risk of vitamin C deﬁcit is the
human species’ maladaptive evolutionary mutation of losing its ability to
synthesize vitamin C endogenously [5].
There is evidence associating low body reserves of vitamin C and vitamin D with relative immune deﬁcit and higher risk of infections [6,7].
Consequently, there is growing support for interventions aimed at raising body reserves of vitamin C, with clinical beneﬁts shown in viral illnesses
[8], sepsis [9], and critical illness [10].
Interventions aimed at raising reserves of vitamin D, while suggestive of
a role in preventing viral infections [1–3,11], are awaiting conﬁrmation of
a role for acute oral/enteral supplementation in acute critical illness [12].
The current COVID-19 pandemic provides an opportunity to explore
whether deﬁcits in vitamin C and/or vitamin D increase the risk of SARSCoV-2 infection, or poor outcomes in COVID-19, and whether acute supplementation of vitamin C and/or vitamin D modiﬁes those risks [13,14].
This pilot study aimed to measure serum vitamin C and vitamin D levels
in a cohort of patients with critical COVID-19 illness in our community hospital ICU, correlate with other illness risk factors (age, BMI, HgbA1c,
smoking status), generate hypotheses, and suggest further therapeutic intervention studies.
2. Method
This pilot study included all 21 critically ill COVID-19 patients hospitalized in May 2020 in the ICU of North Suburban Medical Center, Thornton,
Colorado, in whose care the principal investigator (C.A.) was involved.
Their demographics are shown in the Tables below. All patients had
consented to standard of care investigation and treatment. Collection of
lab samples, including serum vitamin C and vitamin D levels, were part of
the routine immunologic assessment of their severe infectious disease. All
variables in this study were described using descriptive statistics. To compare serum level for survivors and non-survivors we used t-test for independent samples. For all statistical tests, an alpha level of 0.05 or less was
considered statistically signiﬁcant. All statistical analysis was done using
SAS 9.4 version, SAS Institute, Cary, NC.
3. Results
Of our 21 critically ill COVID-19 patients, 11 survived (48% mortality).
Patients' demographic data and vitamin C and D levels are provided in
Table 1 and Fig. 1.
Serum levels of vitamin C and vitamin D2 and D3 were low in most
patients of our cohort, compared with the normal ranges in our hospital
laboratory for vitamin C (17–154 μmol/L) and vitamin D2 and D3 (30–
100 ng/mL).

4. Discussion
In this small pilot research study, most of our critically ill COVID-19 patients had low serum levels of vitamin C and vitamin D. The normal ranges
used by our hospital laboratory for vitamin C (17–154 umol/L) and vitamin
D2 and D3 (30–100 ng/mL) are overly broad, which might underestimate

Table 1
Description of cohort of critically ill COVID patients admitted to this community ICU.
Patient characteristic

Total
(N = 21)

Survivor
(N = 11)

Non-survivor
(N = 10)

6 (28.6%)
15
(71.4%)

3 (27.3%)
8 (72.7%)

3 (30.0%)
7 (70.0%)

Race (N, %)
Caucasian
Hispanic
Age years (mean, SD)

4 (19.1%)
17 (80.9)
60.2 (17.4)

0 (0.0%)
10 (100.0%)
69.1 (15.5)

0.0215

BMI (mean, SD)
HgbA1c (mean, SD)
Vitamin C level μmol/L (mean, SD)

31.6 (7.3)
7.6 (2.0)
22.2 (18.3)

30.2 (7.6)
7.2 (1.2)
15.4 (7.6)

0.4593
0.4059
0.1063

Vitamin D2 D3 ng/mL (mean, SD)

22.0 (9.5)

4 (36.4%)
7 (63.6%)
52.2
(15.3)
32.7 (7.1)
8.0 (2.5)
29.1
(23.3)
21.3
(11.3)

22.8 (7.7)

0.7242

Gender (N, %)
Female
Male

p-Value
0.8901

0.0902⁎

⁎ p Value for Fisher exact test.
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Fig. 1. Serum levels of vit C (μmol/L) and vit D (ng/mL) in critically ill COVID-19 ICU patients, and reference lab ranges.

the vitamin C and vitamin D deﬁcits of the general population, and our
study sample.
Many patients in our cohort were insulin-resistant or diabetic, which is
a risk factor for low vitamin C and vitamin D levels, and for COVID-19
[3,6,11].
Many patients in our cohort were overweight or obese, which is also a
risk factor for low vitamin C and vitamin D levels, and for COVID-19
[2,3,7].
Most of our critically ill COVID-19 patients were non-white (17 Hispanic, 4 white), disproportionate to the local demographics of our hospital’s
suburban Colorado community, suggesting a higher risk of COVID-19 morbidity for Hispanics. Populational studies report a higher incidence of

vitamin D deﬁcit in individuals with darker skin tones [7], and our study results may correlate with that observation. Of note, African Americans are
only a small demographic fraction in our hospital’s suburban Colorado
community, and none was present in this cohort.
Older age and low vitamin C level appeared co-dependent risk factors
for mortality from COVID-19 in our sample, which is in line with the international experience [6]. Irrespective of all unknown covariates, serum vitamin C contributed to the signiﬁcance of age as a predictor of mortality
(conversely, without a serum vitamin C level, age became non-signiﬁcant).
Our study has several limitations. The study sample was too small to detect statistically signiﬁcant differences in serum vitamin C and vitamin D
levels between survivors and nonsurvivors.

Fig. 2. Univariate (unadjusted) odds ratios for mortality as outcome, and age, and
level of serum vitamin C as separate (one at a time) predictors among patients
diagnosed with COVID-19, using two separate regression models. When age, and
all other unknown covariates, and serum vitamin C level are considered, age
becomes a signiﬁcant predictor of mortality.

Fig. 3. Multivariate (adjusted) Odds ratios for mortality as outcome, and age, and
level of serum vitamin C (together), as predictors among patients diagnosed with
COVID-19, using multivariate regression model. When age and all other unknown
covariates are considered, but serum vitamin C level is not, age becomes a nonsigniﬁcant predictor of mortality.
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Our study lacked a longitudinal, pre-morbid follow-up of serum vitamin C
and vitamin D levels in the same cohort, or a control group of serum vitamin
C and vitamin D levels in healthy subjects matched for demographics and
other risk factors, which precludes ﬁrm conclusions whether low serum
levels of vitamin C and vitamin D are a risk factor for, versus a consequence
of, acquiring SARS-CoV-2, or having a severe form of COVID-19. Critical illness is often associated with low serum vitamin C levels, due to metabolic
consumption. However, we cannot exclude the possibility that chronic,
pre-existing low serum vitamin C levels may increase the risk for, and severity of, COVID-19 [18].
The ﬁndings of our small pilot study might generate hypotheses, and
contribute impetus for further therapeutic intervention studies, with questions like:
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− Should those at risk for, or newly diagnosed with, SARS-CoV-2 infection
have their serum vitamin C and vitamin D levels measured, and started
on pre-emptive supplementation to lower risk of COVID-19, and severe
forms [3,11]?
− Should those infected with SARS-CoV-2, and with additional risk factors
(the elderly, diabetics, and/or obese) receive rapid and higher-dose replacement and supplementation of vitamin C and vitamin D, to lower
risk of COVID-19, and severe forms [5,9,11,12]?
− Should those with severe or critical COVID-19, and whose critical illness
might impair the enteral absorption of vitamin C [10] and vitamin D [16],
receive urgent, parenteral, high-dose replacement and supplementation of
vitamin C [4,9,10,13,15] and vitamin D [14,16,17]?

5. Conclusion
This pilot study found low serum levels of vitamin C and vitamin D in
most of our critically ill COVID-19 ICU patients. Older age and low vitamin
C level appeared co-dependent risk factors for mortality.
Many were also insulin-resistant or diabetic, overweight or obese,
which had been reported as independent risk factors for low vitamin C
and vitamin D levels, and for COVID-19.
These ﬁndings suggest the need to further explore whether caring for
COVID-19 patients ought to routinely include measuring and correcting
serum vitamin C and vitamin D levels, and whether treating critically ill
COVID-19 warrants acute parenteral vitamin C and vitamin D replacement.
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